257 related articles for article (PubMed ID: 28283727)
1. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America.
Mithal LB; Patel PS; Mithal D; Palac HL; Rozenfeld MN
Pediatr Radiol; 2017 May; 47(6):657-664. PubMed ID: 28283727
[TBL] [Abstract][Full Text] [Related]
2. Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.
Blumfield E; Moore MM; Drake MK; Goodman TR; Lewis KN; Meyer LT; Ngo TD; Sammet C; Stanescu AL; Swenson DW; Slovis TL; Iyer RS
Pediatr Radiol; 2017 May; 47(6):665-673. PubMed ID: 28283728
[TBL] [Abstract][Full Text] [Related]
3. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.
Stanescu AL; Shaw DW; Murata N; Murata K; Rutledge JC; Maloney E; Maravilla KR
Pediatr Radiol; 2020 Mar; 50(3):388-396. PubMed ID: 31989188
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium Deposition in the Brain in a Large Animal Model: Comparison of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Richter H; Fingerhut S; Martin LF; Xia A; Henze N; Paulus W; Sperling M; Karst U; Jeibmann A
Invest Radiol; 2019 Sep; 54(9):531-536. PubMed ID: 31261291
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.
Tibussek D; Rademacher C; Caspers J; Turowski B; Schaper J; Antoch G; Klee D
Radiology; 2017 Oct; 285(1):223-230. PubMed ID: 28640695
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Gadolinium Deposition on Radiology Practice: An International Survey of Radiologists.
Fitzgerald RT; Agarwal V; Hoang JK; Gaillard F; Dixon A; Kanal E
Curr Probl Diagn Radiol; 2019; 48(3):220-223. PubMed ID: 29530452
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists.
Costa AF; van der Pol CB; Maralani PJ; McInnes MDF; Shewchuk JR; Verma R; Hurrell C; Schieda N
Can Assoc Radiol J; 2018 Nov; 69(4):373-382. PubMed ID: 30249408
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents.
Richter H; Bücker P; Martin LF; Dunker C; Fingerhut S; Xia A; Karol A; Sperling M; Karst U; Radbruch A; Jeibmann A
Radiology; 2021 Dec; 301(3):637-642. PubMed ID: 34546128
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium Deposition and Chronic Toxicity.
Ramalho J; Ramalho M
Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
[TBL] [Abstract][Full Text] [Related]
10. Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study.
Perrotta G; Metens T; Absil J; Lemort M; Manto M
J Neurol; 2017 Nov; 264(11):2277-2283. PubMed ID: 28956156
[TBL] [Abstract][Full Text] [Related]
11. The use of gadolinium-based contrast agents in Ghana with a focus on residual intracranial gadolinium deposition.
Piersson AD; Gorleku PN
Radiography (Lond); 2018 Aug; 24(3):e51-e55. PubMed ID: 29976344
[TBL] [Abstract][Full Text] [Related]
12. Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: An observational study.
Eisele P; Alonso A; Szabo K; Ebert A; Ong M; Schoenberg SO; Gass A
Medicine (Baltimore); 2016 Sep; 95(39):e4624. PubMed ID: 27684794
[TBL] [Abstract][Full Text] [Related]
13. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
Runge VM
Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
15. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.
Roberts DR; Lindhorst SM; Welsh CT; Maravilla KR; Herring MN; Braun KA; Thiers BH; Davis WC
Invest Radiol; 2016 May; 51(5):280-9. PubMed ID: 26953564
[TBL] [Abstract][Full Text] [Related]
16. Practical recommendations for the safe use of gadolinium in magnetic resonance imaging: a Delphi expert panel study.
Baroni RH; Bauab T; Bittencourt LK; D'Ippolito G; Goldman SM; Hohgraefe Neto G; Manzella A; Rocha AJ; Sonoda LA; Takeda FS
Radiol Bras; 2020; 53(4):216-222. PubMed ID: 32904664
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.
Radbruch A; Weberling LD; Kieslich PJ; Eidel O; Burth S; Kickingereder P; Heiland S; Wick W; Schlemmer HP; Bendszus M
Radiology; 2015 Jun; 275(3):783-91. PubMed ID: 25848905
[TBL] [Abstract][Full Text] [Related]
18. Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.
Ayyala RS; Anupindi SA; Gee MS; Trout AT; Callahan MJ
Pediatr Radiol; 2019 Sep; 49(10):1256-1268. PubMed ID: 31350632
[TBL] [Abstract][Full Text] [Related]
19. Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: Multifactorial analysis in 385 patients.
Lee JY; Park JE; Kim HS; Kim SO; Oh JY; Shim WH; Jung SC; Choi CG; Kim SJ
PLoS One; 2017; 12(8):e0183916. PubMed ID: 28859167
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium Deposition: A Study Review.
Strickler SE; Clark KR
Radiol Technol; 2021 Jan; 92(3):249-258. PubMed ID: 33472877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
